Patient-Alert-Card

This document is approved by The Executive Directorate of Pharmacovigilance, at SFDA

TREATMENT WITH METHOTREXATE VENUS

"Methotrexate Injection USP **50 mg/2ml**"

Patient's name: _____

Treatment day: _____

Patient's dose: _____

Physician's name and phone number: _____

Important safety information

Drug information and Indication: Methotrexate Injection is an anti-metabolite medicine (medicine which affects how the body's cells grow) and immunosuppressant (medicine which reduces the activity of the immune system). Methotrexate is indicated in the treatment of neoplastic disease, such as trophoblastic neoplasms and leukaemia, and the symptomatic treatment of severe recalcitrant disabling psoriasis which is not adequately responsive to other forms of therapy.

Brief warning:

- Do not take more than the prescribed dose and if you are allergic (hypersensitive) to Methotrexate.
- If you have severe reaction or having spitting or coughing up blood, contact a doctor straight away.
- Symptoms of overdose include sore throat, fever, mouth ulcers, diarrhoea, vomiting, skin rashes, bleeding or unusual weakness.
- Use Methotrexate Injection only once a week for the treatment of psoriasis.
- Alcohol consumption should be avoided while being treated with methotrexate.
- The medicinal product is (potentially) fetal teratogenic and requires use of effective contraception during treatment and for at least six months after.
- Always show this card to healthcare professionals not familiar with your methotrexate treatment to alert them about your treatment eg if you go to hospital or have a change in care.
- If you are taking other medicines also, pls discuss with your doctor.
- For more information, please read the patient leaflet in your medicine pack

To report adverse events or safety concerns, contact:

Mesned Pharma Consult Center Pharmacovigilance Department on behalf of Venus:

- E-mail: mpv@mesned.com

The National Pharmacovigilance Centre (NPC) Saudi Food and Drug Authority (SFDA):

- Unified SFDA call center: 19999
- E-mail: npc.drug@sfda.gov.sa
- Website: https://ade.sfda.gov.sa/

Version 03 date: 10-2023
METHOTREXATE VENUS